|Bid||12.15 x 900|
|Ask||12.67 x 40000|
|Day's Range||11.77 - 12.94|
|52 Week Range||8.53 - 22.55|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced it has completed an analysis of the SARS-CoV-2 B.1.1.529 variant, designated by the World Health Organization as Omicron. Using information from the GISAID database, Cue has determined its COVID-19 tests, which uses molecular (NAAT) technology, can detect the Omicron variant. Specifically, Cue found that 99.2% of the available 127 published sequences are a perfect match to the primers used in the Company's tests.
Helix, a leading genomics company that provides nationwide viral surveillance of respiratory disease, and Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, announced a new collaboration today to provide individuals who test positive on Cue's at-home molecular COVID-19 test the opportunity to learn which variant they have contracted as part of a broader research study on the SARS-CoV-2 virus.
View more earnings on HLTHSee more from BenzingaClick here for options trades from BenzingaFDA Clears Sight Sciences' Trial Of Canaloplasty Combined With Cataract Surgery To Lower Ocular PressureKORU Medical Shares Surge On FDA Approval For FreedomEdge Infusion Pump© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.